Uma Mahadevan, MD
Professor of Medicine, Division of Gastroenterology
Director, Center for Colitis and Crohn’s Disease
University of California San Francisco Medical School
San Francisco, California
Uma Mahadevan, MD, has disclosed that she has received consulting fees from AbbVie, Arena, Bristol-Myers Squibb, Boehringer Ingelheim, Calibr, Gilead, Janssen, Pfizer, Prometheus Biosciences, Protagonist, Surrozen, and Takeda.
Bruce E. Sands, MD, MS
Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology
Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York
Bruce E. Sands, MD, MS, has disclosed that he has received funds for research support from Janssen and Theravance Biopharma R&D; has received consulting fees from Abivax, AbbVie, Alimentiv, Amgen, Arena, Artugen, AstraZeneca, Bacainn, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol-Myers Squibb, Calibr, Celltrion, ClostraBio, Enthera, Evommune, Ferring, Galapagos, Gilead, GlaxoSmithKline, GossamerBio, Immunic, Index, Innovation, Ironwood, Janssen, Kaleido, Kallyope, Lilly, MiroBio, MRM Health, Morphic Therapeutic, Pfizer, Progenity, Prometheus Biosciences, Protagonist Therapeutics, Q32 Bio, Sun Pharma, Surrozen, Takeda, Target RWE, Teva Branded Pharmaceutical Products R&D, Thelium, Theravance Biopharma R&D, TLL Pharma, USWM Enterprises, Ventyx Biosciences, Viela Bio; and has ownership interest in Ventyx.